Results 151 to 160 of about 10,687 (160)
Some of the next articles are maybe not open access.
Effects of O‐1602 and CBD on TNBS‐induced colonic disturbances
Neurogastroenterology & Motility, 2019AbstractBackgroundThis study attempted to provide the effects and mechanisms of two cannabinoids, O‐1602 and cannabidiol (CBD), on colonic motility of 2,4,6‐trinitro‐benzene sulfonic acid (TNBS) colitis.MethodsTNBS was used to induce the model of motility disorder.
DanDan Wei +7 more
openaire +2 more sources
The atypical cannabinoid O‐1602 stimulates food intake and adiposity in rats
Diabetes, Obesity and Metabolism, 2011Aims: Cannabinoids are known to control energy homeostasis. Atypical cannabinoids produce pharmacological effects via unidentified targets. We sought to investigate whether the atypical cannabinoid O‐1602 controls food intake and body weight. Methods:
Díaz-Arteaga, A. +12 more
openaire +2 more sources
European Journal of Pharmacology, 2015
Atypical cannabinoid O-1602 (5-Methyl-4-[(1R,6R)-3-methyl-6-(1-cyclohexen-1-yl]-1,3-benzenediol) induces vasorelaxation and activates the orphan G protein-coupled receptor GPR55 in human endothelial cells. This study investigates the underlying mechanisms of vasorelaxation induced by this compound. The vasodilator activity was assessed in the rat third
Y M, Al Suleimani +2 more
openaire +2 more sources
Atypical cannabinoid O-1602 (5-Methyl-4-[(1R,6R)-3-methyl-6-(1-cyclohexen-1-yl]-1,3-benzenediol) induces vasorelaxation and activates the orphan G protein-coupled receptor GPR55 in human endothelial cells. This study investigates the underlying mechanisms of vasorelaxation induced by this compound. The vasodilator activity was assessed in the rat third
Y M, Al Suleimani +2 more
openaire +2 more sources
Pharmacological Reports, 2016
Previous studies show that some non-CB1/non-CB2 effects of cannabinoids are mediated through G protein coupled receptor 55 (GPR55). As this receptor is activated by some of cannabinoid receptor ligands and is involved in the modulation of pain, it was hypothesized that this receptor may also interact with opioids.
Mohaddeseh Sadat Alavi +3 more
openaire +2 more sources
Previous studies show that some non-CB1/non-CB2 effects of cannabinoids are mediated through G protein coupled receptor 55 (GPR55). As this receptor is activated by some of cannabinoid receptor ligands and is involved in the modulation of pain, it was hypothesized that this receptor may also interact with opioids.
Mohaddeseh Sadat Alavi +3 more
openaire +2 more sources
Neuroscience Letters, 2012
O-1602 is an atypical cannabinoid that acts as an agonist at GPR55, a g protein-coupled receptor that previous studies have indicated may have a pronociceptive role in neuropathic pain. We administered O-1602 to both naive rats and rats that had undergone chronic constriction injury surgery. O-1602 did not cause any changes in hind paw responses to Von
Courtney, Breen +2 more
openaire +2 more sources
O-1602 is an atypical cannabinoid that acts as an agonist at GPR55, a g protein-coupled receptor that previous studies have indicated may have a pronociceptive role in neuropathic pain. We administered O-1602 to both naive rats and rats that had undergone chronic constriction injury surgery. O-1602 did not cause any changes in hind paw responses to Von
Courtney, Breen +2 more
openaire +2 more sources
The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry, 2012O-1602 is a cannabidiol analogue that does not bind with high affinity to either the cannabinoid CB1 receptor or CB2 receptor. However, there is evidence that O-1602 has significant effects in the central nervous system as well as other parts of the body. Depending upon the model, O-1602 has anti-inflammatory or pronociceptive effects, mediated through
openaire +2 more sources
Obesity Research & Clinical Practice, 2014
Background: Childhood obesity prevalence, previously at a disturbing upward trend, appears to be holding at a steady rate. The purpose of this study was to investigate current levels of obesity prevalence in a sample of low socioeconomic preadolescent children and examine associations with physical activity, sedentary and eating behaviour.
Anna C. Simcocks +5 more
openaire +1 more source
Background: Childhood obesity prevalence, previously at a disturbing upward trend, appears to be holding at a steady rate. The purpose of this study was to investigate current levels of obesity prevalence in a sample of low socioeconomic preadolescent children and examine associations with physical activity, sedentary and eating behaviour.
Anna C. Simcocks +5 more
openaire +1 more source
Neuroscience Letters, 2011
Cannabinoids classically act via CB₁ and CB₂ receptors to modulate nociception; however, recent findings suggest that some cannabinoids bind to atypical receptors. One such receptor is GPR55 which is activated by the abnormal cannabidiol analogue O-1602. This study investigated whether the synthetic GPR55 agonist O-1602 can alter joint nociception in a
Niklas, Schuelert, Jason J, McDougall
openaire +2 more sources
Cannabinoids classically act via CB₁ and CB₂ receptors to modulate nociception; however, recent findings suggest that some cannabinoids bind to atypical receptors. One such receptor is GPR55 which is activated by the abnormal cannabidiol analogue O-1602. This study investigated whether the synthetic GPR55 agonist O-1602 can alter joint nociception in a
Niklas, Schuelert, Jason J, McDougall
openaire +2 more sources
Chronic administration of O-1602 diminishes adiposity in diet induced obese rat model
Obesity Research & Clinical Practice, 2013Anna Simcocks (nee Roy) +5 more
openaire +1 more source
Obesity Research & Clinical Practice, 2012
A. Simcocks, D. Hryciw, A. McAinch
openaire +1 more source
A. Simcocks, D. Hryciw, A. McAinch
openaire +1 more source